Company Flex Pharma Inc Nasdaq
Equities
US33938A1051
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-18 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 19-09-09 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-18 |
Nadeem Q. Mirza
PRN | Corporate Officer/Principal | - | 20-07-22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19-07-18 |
Paul Lammers
BRD | Director/Board Member | 66 | 19-07-18 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 20-06-18 |
William McVicar
CHM | Chairman | 66 | 19-07-18 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-18 |
Tess Burleson
BRD | Director/Board Member | 57 | 19-07-18 |
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 597,054 | 560,776 ( 93.92 %) | 0 | 93.92 % |
Company contact information
Salarius Pharmaceuticals, Inc.
2450 Holcombe Boulevard Suite X
77021, Houston
+
http://salariuspharma.comSector
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |